Search Bar & Filters
Found 3 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating camizestrant compared to standard endocrine therapy in patients with ER-positive, HER2-negative early breast cancer who have an intermediate or high risk of disease recurrence. This Phase III open-label study includes patients who have completed definitive locoregional therapy, with or without chemotherapy, and have received standard adjuvant endocrine therapy for at least 2 years and up to 5 years. The study aims to determine if camizestrant improves invasive breast cancer-free survival and other important outcomes over a long-term follow-up. Participants will be randomly assigned to receive either camizestrant orally or continue standard endocrine therapy chosen by their doctor, which may include aromatase inhibitors like exemestane, letrozole, anastrozole, or tamoxifen. Treatment in both groups will last for up to 60 months. The study allows prior use of CDK46 inhibitors and includes an open-label design where both participants and researchers know the assigned treatment. During the study, participants will be monitored with assessments including survival outcomes, disease-free survival, relapse-free survival, and overall survival for up to 10 years from the last patient randomized. Safety will be tracked through adverse event reporting, laboratory and vital signs tests, and symptom questionnaires measuring arthralgia, hot flushes, vaginal dryness, and quality of life. Pharmacokinetics will be studied up to 6 months after treatment starts. The total duration of participation can extend over many years to capture long-term results.
Actively Recruiting
Researchers are evaluating a new patient-reported outcome PRO tool designed to detect infections in adults with chronic lymphocytic leukemia CLL or multiple myeloma MM who have secondary immunodeficiency SID. The study aims to improve infection detection and track changes in quality of life over time in this vulnerable group. This observational study is conducted at multiple centers in Germany and Austria and involves patients starting anticancer therapy. Participants will use a mobile app daily to complete electronic PRO questionnaires about infection-related symptoms. Quality of life questionnaires are completed every 1.5 months. Study visits occur every three months to document clinical data such as treatment updates, disease status, and infection history. The app was developed based on a tested software platform and includes features like push reminders to encourage daily symptom reporting. During the year-long participation, researchers will monitor the accuracy of the PRO tool in detecting infections, evaluate adherence to daily reporting, and assess quality of life using validated instruments. Clinical data will be collected and infections documented during quarterly visits. Patient safety and confidentiality are maintained according to ethical standards throughout the study.
Actively Recruiting
Researchers are studying metastatic breast cancer, the most common cancer among women worldwide, with a focus on patients in Austria. This study is the first Austrian-wide registry to systematically collect and document data on metastatic breast cancer cases. The aim is to understand epidemiological trends and treatment patterns, including tumor characteristics and patient outcomes. The study collects both retrospective and prospective data from multiple centers across Austria. It records detailed information on tumor subtypes, initial disease progression, treatment sequences, and patient medical histories. This registry also includes data on male breast cancer patients to assess gender differences in treatment and outcomes. Participants provide anonymized medical information, including tumor characteristics, treatment details, and survival data. Researchers will analyze patterns of metastasis, treatment responses, and survival rates at 1, 2, and 5 years after metastasis diagnosis. The registry aims to offer insights into treatment quality and outcomes over a 10-year period.